- Latest available (Revised)
- Point in Time (01/12/2009)
- Original (As adopted by EU)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under document number C(2002) 1344) (Text with EEA relevance) (2002/364/EC) is up to date with all changes known to be in force on or before 28 September 2024. There are changes that may be brought into force at a future date.
Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.
Article 1.The technical specifications set out in the Annex to this...
COMMON TECHNICAL SPECIFICATIONS (CTS) FOR IN VITRO DIAGNOSTIC MEDICAL DEVICES
3. COMMON TECHNICAL SPECIFICATIONS (CTS) FOR PRODUCTS REFERRED TO IN ANNEX...
3.1. CTS for performance evaluation of reagents and reagent products for...
3.1.1. Devices which detect virus infections placed on the market for...
3.1.2. Devices intended by the manufacturer for testing body fluids other...
3.1.3. Devices intended by the manufacturer for self-test, i.e. home use,...
3.1.4. All performance evaluations shall be carried out in direct comparison...
3.1.5. If discrepant test results are identified as part of an...
3.1.6. Performance evaluations shall be performed on a population equivalent to...
3.1.7. Positive specimens used in the performance evaluation shall be selected...
3.1.8. Sensitivity with true positives and sero-conversion samples shall be evaluated...
3.1.9. Performance evaluation of screening assays shall include 25 positive (if...
3.1.10. Negative specimens used in a performance evaluation shall be defined...
3.1.11. For performance evaluations for screening assays (Table 1) blood donor...
3.1.12. Devices shall have a specificity of at least 99,5 %...
3.1.13. Devices shall be evaluated to establish the effect of potential...
3.1.14. For devices intended by the manufacturer to be used with...
3.1.15. For devices intended for use with plasma the performance evaluation...
3.1.16. As part of the required risk analysis the whole system...
3.1.17. If a new in vitro diagnostic medical device belonging to...
3.2. Additional requirements for HIV antibody/antigen combined tests
3.3. Additional requirements for nucleic acid amplification techniques (NAT)
3.3.1. For target sequence amplification assays, a functionality control for each...
3.3.2. The analytical sensitivity or detection limit for NAT assays shall...
3.3.3. Genotype detection shall be demonstrated by appropriate primer or probe...
3.3.4. Results of quantitative NAT assays shall be traceable to international...
3.3.5. NAT assays may be used to detect virus in antibody...
3.3.6. For investigation of potential carry-over, at least five runs with...
3.3.7. The whole system failure rate leading to false-negative results shall...
3.4. CTS for the manufacturer’s release testing of reagents and reagent...
3.5. CTS for performance evaluation of reagents and reagent products for...
3.5.1. All performance evaluations shall be carried out in direct comparison...
3.5.2. If discrepant test results are identified as part of an...
3.5.3. Performance evaluations shall be performed on a population equivalent to...
3.5.4. Positive specimens used in the performance evaluation shall be selected...
3.5.5. Devices shall be evaluated to establish the effect of potential...
3.5.6. For devices intended for use with plasma the performance evaluation...
3.6. CTS for the manufacturer’s release testing of reagents and reagent...
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: